Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgery, Plastic | 21 | 2023 | 109 | 8.650 |
Why?
|
| Mammaplasty | 10 | 2023 | 44 | 4.430 |
Why?
|
| Surgical Flaps | 6 | 2022 | 179 | 2.380 |
Why?
|
| Surgeons | 7 | 2022 | 292 | 1.920 |
Why?
|
| Internship and Residency | 8 | 2022 | 1218 | 1.880 |
Why?
|
| Breast Implants | 5 | 2026 | 30 | 1.470 |
Why?
|
| Breast Implantation | 4 | 2024 | 9 | 1.380 |
Why?
|
| Student Run Clinic | 2 | 2021 | 3 | 1.310 |
Why?
|
| Cosmetic Techniques | 2 | 2021 | 11 | 1.290 |
Why?
|
| Free Tissue Flaps | 2 | 2022 | 49 | 1.150 |
Why?
|
| Perforator Flap | 3 | 2023 | 8 | 1.120 |
Why?
|
| Nipples | 2 | 2020 | 8 | 1.110 |
Why?
|
| Postoperative Complications | 5 | 2026 | 3115 | 1.020 |
Why?
|
| Informed Consent | 2 | 2020 | 352 | 1.010 |
Why?
|
| Relative Value Scales | 2 | 2022 | 13 | 0.930 |
Why?
|
| Pneumonectomy | 1 | 2026 | 154 | 0.840 |
Why?
|
| Licensure, Medical | 2 | 2021 | 22 | 0.830 |
Why?
|
| Rhinoplasty | 2 | 2023 | 54 | 0.830 |
Why?
|
| Journal Impact Factor | 2 | 2021 | 26 | 0.810 |
Why?
|
| Bibliometrics | 2 | 2021 | 36 | 0.800 |
Why?
|
| Abdominoplasty | 1 | 2022 | 2 | 0.760 |
Why?
|
| Seroma | 2 | 2024 | 8 | 0.720 |
Why?
|
| Mandibular Fractures | 1 | 2022 | 10 | 0.720 |
Why?
|
| Clinical Coding | 1 | 2022 | 15 | 0.720 |
Why?
|
| Employee Performance Appraisal | 1 | 2022 | 12 | 0.710 |
Why?
|
| Nose Deformities, Acquired | 1 | 2021 | 14 | 0.710 |
Why?
|
| Acellular Dermis | 2 | 2019 | 7 | 0.710 |
Why?
|
| Physician Executives | 1 | 2022 | 33 | 0.710 |
Why?
|
| Reimbursement Mechanisms | 1 | 2022 | 36 | 0.700 |
Why?
|
| Inventions | 1 | 2021 | 19 | 0.690 |
Why?
|
| Embolism, Fat | 1 | 2021 | 6 | 0.690 |
Why?
|
| Thoracotomy | 1 | 2022 | 107 | 0.680 |
Why?
|
| Biomedical Technology | 1 | 2021 | 38 | 0.670 |
Why?
|
| Raynaud Disease | 1 | 2020 | 3 | 0.670 |
Why?
|
| Transplant Donor Site | 1 | 2020 | 6 | 0.660 |
Why?
|
| Humans | 60 | 2026 | 130555 | 0.660 |
Why?
|
| Commerce | 1 | 2021 | 58 | 0.660 |
Why?
|
| Personnel Selection | 1 | 2022 | 79 | 0.660 |
Why?
|
| Academic Performance | 1 | 2020 | 24 | 0.650 |
Why?
|
| Job Application | 1 | 2020 | 21 | 0.650 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2020 | 38 | 0.650 |
Why?
|
| Research Personnel | 1 | 2022 | 141 | 0.630 |
Why?
|
| Conflict of Interest | 2 | 2022 | 66 | 0.630 |
Why?
|
| Breast | 5 | 2024 | 213 | 0.630 |
Why?
|
| Ownership | 1 | 2020 | 34 | 0.620 |
Why?
|
| Disclosure | 2 | 2021 | 150 | 0.610 |
Why?
|
| Professional Role | 1 | 2020 | 78 | 0.600 |
Why?
|
| Photography | 1 | 2020 | 79 | 0.600 |
Why?
|
| Confidentiality | 1 | 2020 | 108 | 0.590 |
Why?
|
| Infection Control | 1 | 2020 | 162 | 0.580 |
Why?
|
| Surgical Mesh | 1 | 2019 | 64 | 0.570 |
Why?
|
| Simulation Training | 1 | 2020 | 170 | 0.530 |
Why?
|
| Faculty, Medical | 1 | 2020 | 281 | 0.510 |
Why?
|
| Betacoronavirus | 1 | 2020 | 282 | 0.510 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 461 | 0.500 |
Why?
|
| Biomedical Research | 2 | 2023 | 558 | 0.490 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 224 | 0.480 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 351 | 0.460 |
Why?
|
| Spinal Fusion | 3 | 2021 | 125 | 0.460 |
Why?
|
| Fibrosis | 2 | 2014 | 419 | 0.450 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 1004 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 351 | 0.450 |
Why?
|
| Antigens, CD | 2 | 2014 | 410 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 363 | 0.450 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 2602 | 0.450 |
Why?
|
| Microsurgery | 1 | 2015 | 66 | 0.430 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 127 | 0.420 |
Why?
|
| United States | 12 | 2024 | 11883 | 0.420 |
Why?
|
| Decision Making | 2 | 2020 | 711 | 0.400 |
Why?
|
| Telemedicine | 1 | 2020 | 526 | 0.400 |
Why?
|
| Spinal Diseases | 2 | 2026 | 46 | 0.400 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 679 | 0.380 |
Why?
|
| Operative Time | 3 | 2026 | 199 | 0.380 |
Why?
|
| Pandemics | 1 | 2020 | 1157 | 0.380 |
Why?
|
| Neuromuscular Agents | 1 | 2013 | 64 | 0.380 |
Why?
|
| Hypoxia | 1 | 2014 | 247 | 0.370 |
Why?
|
| Transforming Growth Factor beta | 2 | 2014 | 451 | 0.360 |
Why?
|
| Bone Transplantation | 4 | 2026 | 54 | 0.360 |
Why?
|
| Treatment Outcome | 10 | 2026 | 12865 | 0.360 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 292 | 0.350 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2013 | 127 | 0.350 |
Why?
|
| Transplantation, Autologous | 4 | 2021 | 254 | 0.340 |
Why?
|
| Tissue Expansion Devices | 2 | 2026 | 10 | 0.340 |
Why?
|
| Burnout, Professional | 3 | 2021 | 134 | 0.330 |
Why?
|
| Databases, Factual | 3 | 2024 | 1231 | 0.320 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2021 | 69 | 0.300 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2023 | 49 | 0.280 |
Why?
|
| Retrospective Studies | 9 | 2026 | 17557 | 0.270 |
Why?
|
| Female | 20 | 2026 | 70425 | 0.260 |
Why?
|
| Oxygen | 2 | 2023 | 550 | 0.240 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 439 | 0.240 |
Why?
|
| Hypertrophy | 2 | 2023 | 99 | 0.240 |
Why?
|
| Spinal Neoplasms | 1 | 2026 | 76 | 0.230 |
Why?
|
| Thigh | 2 | 2023 | 51 | 0.220 |
Why?
|
| Wound Healing | 3 | 2014 | 486 | 0.220 |
Why?
|
| Syndrome | 2 | 2026 | 1158 | 0.210 |
Why?
|
| Esthetics | 3 | 2024 | 38 | 0.210 |
Why?
|
| Nose | 2 | 2023 | 114 | 0.210 |
Why?
|
| Aneuploidy | 1 | 2024 | 136 | 0.210 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 350 | 0.200 |
Why?
|
| Gracilis Muscle | 1 | 2023 | 4 | 0.200 |
Why?
|
| Epithelial Cells | 2 | 2024 | 907 | 0.190 |
Why?
|
| Body Contouring | 1 | 2022 | 1 | 0.190 |
Why?
|
| Cell Lineage | 1 | 2024 | 341 | 0.190 |
Why?
|
| Epigastric Arteries | 1 | 2022 | 6 | 0.190 |
Why?
|
| Umbilicus | 1 | 2022 | 13 | 0.190 |
Why?
|
| Open Access Publishing | 1 | 2022 | 3 | 0.180 |
Why?
|
| Mastectomy | 2 | 2020 | 74 | 0.180 |
Why?
|
| Contracts | 1 | 2022 | 11 | 0.180 |
Why?
|
| Scleroderma, Systemic | 2 | 2014 | 117 | 0.180 |
Why?
|
| Negotiating | 1 | 2022 | 13 | 0.180 |
Why?
|
| Implant Capsular Contracture | 1 | 2021 | 1 | 0.170 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2021 | 2 | 0.170 |
Why?
|
| Buttocks | 1 | 2021 | 5 | 0.170 |
Why?
|
| Private Practice | 1 | 2021 | 21 | 0.170 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 19 | 0.170 |
Why?
|
| Equipment and Supplies | 1 | 2021 | 28 | 0.170 |
Why?
|
| Prone Position | 1 | 2021 | 31 | 0.170 |
Why?
|
| Facial Injuries | 1 | 2021 | 24 | 0.170 |
Why?
|
| Autografts | 1 | 2021 | 28 | 0.170 |
Why?
|
| Kyphosis | 1 | 2021 | 23 | 0.170 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 48 | 0.170 |
Why?
|
| Superficial Back Muscles | 1 | 2020 | 2 | 0.170 |
Why?
|
| Patient Positioning | 1 | 2021 | 51 | 0.170 |
Why?
|
| Pressure Ulcer | 1 | 2021 | 69 | 0.170 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 151 | 0.170 |
Why?
|
| Hospitals, County | 1 | 2020 | 22 | 0.160 |
Why?
|
| Surgical Wound | 1 | 2020 | 21 | 0.160 |
Why?
|
| Femoral Artery | 1 | 2021 | 134 | 0.160 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 18 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2022 | 154 | 0.160 |
Why?
|
| Morphine | 1 | 2020 | 80 | 0.160 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2020 | 2 | 0.160 |
Why?
|
| Necrosis | 1 | 2020 | 194 | 0.160 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 109 | 0.160 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2020 | 21 | 0.160 |
Why?
|
| Oncologists | 1 | 2020 | 32 | 0.160 |
Why?
|
| Publications | 1 | 2020 | 36 | 0.160 |
Why?
|
| Marketing of Health Services | 1 | 2020 | 25 | 0.160 |
Why?
|
| Obesity, Morbid | 1 | 2022 | 231 | 0.160 |
Why?
|
| Patients | 1 | 2020 | 123 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 1806 | 0.150 |
Why?
|
| Publishing | 1 | 2021 | 105 | 0.150 |
Why?
|
| Surgical Wound Infection | 1 | 2022 | 265 | 0.150 |
Why?
|
| Device Removal | 1 | 2021 | 222 | 0.150 |
Why?
|
| Reoperation | 1 | 2022 | 811 | 0.150 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 163 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2022 | 182 | 0.150 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 1021 | 0.150 |
Why?
|
| Length of Stay | 2 | 2026 | 1404 | 0.150 |
Why?
|
| Pain Measurement | 1 | 2020 | 349 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2021 | 318 | 0.140 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 337 | 0.140 |
Why?
|
| Pain Management | 1 | 2020 | 205 | 0.140 |
Why?
|
| Adipose Tissue | 1 | 2021 | 499 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 535 | 0.120 |
Why?
|
| Skin, Artificial | 1 | 2016 | 7 | 0.120 |
Why?
|
| Tissue Expansion | 1 | 2016 | 12 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 462 | 0.120 |
Why?
|
| Adult | 8 | 2026 | 31157 | 0.120 |
Why?
|
| Clinical Competence | 2 | 2021 | 1060 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 484 | 0.110 |
Why?
|
| Hemipelvectomy | 1 | 2014 | 2 | 0.110 |
Why?
|
| Erythema | 1 | 2015 | 29 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2014 | 28 | 0.110 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 667 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 93 | 0.100 |
Why?
|
| Graft Survival | 1 | 2016 | 459 | 0.100 |
Why?
|
| Dermis | 1 | 2013 | 26 | 0.100 |
Why?
|
| Melanoma | 1 | 2020 | 927 | 0.100 |
Why?
|
| Cicatrix | 1 | 2014 | 125 | 0.100 |
Why?
|
| Bleomycin | 1 | 2013 | 116 | 0.100 |
Why?
|
| Complement C5 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 904 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 123 | 0.090 |
Why?
|
| Sarcoma | 1 | 2014 | 218 | 0.090 |
Why?
|
| Skin | 2 | 2012 | 539 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 2333 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 556 | 0.090 |
Why?
|
| Complement C3 | 1 | 2011 | 43 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5164 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2011 | 110 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2011 | 117 | 0.080 |
Why?
|
| Middle Aged | 4 | 2026 | 28415 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2011 | 115 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6215 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2020 | 6438 | 0.080 |
Why?
|
| Founder Effect | 1 | 2009 | 32 | 0.080 |
Why?
|
| Cause of Death | 1 | 2011 | 502 | 0.070 |
Why?
|
| Male | 9 | 2026 | 64534 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2011 | 214 | 0.070 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2009 | 65 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2016 | 3678 | 0.070 |
Why?
|
| Fibronectins | 3 | 2013 | 99 | 0.070 |
Why?
|
| Exons | 1 | 2009 | 760 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2011 | 1060 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2011 | 702 | 0.060 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 551 | 0.060 |
Why?
|
| Risk Factors | 1 | 2019 | 10967 | 0.050 |
Why?
|
| Clone Cells | 1 | 2024 | 152 | 0.050 |
Why?
|
| Diffusion | 1 | 2023 | 57 | 0.050 |
Why?
|
| Aged | 4 | 2026 | 20899 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 30 | 0.050 |
Why?
|
| Nasal Septum | 1 | 2023 | 25 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 179 | 0.050 |
Why?
|
| Consumer Behavior | 1 | 2022 | 30 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2012 | 132 | 0.040 |
Why?
|
| Industry | 1 | 2022 | 29 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 154 | 0.040 |
Why?
|
| Cost Savings | 1 | 2022 | 79 | 0.040 |
Why?
|
| Dentition | 1 | 2021 | 5 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2022 | 74 | 0.040 |
Why?
|
| Mammography | 1 | 2022 | 122 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 159 | 0.040 |
Why?
|
| Self Concept | 1 | 2022 | 157 | 0.040 |
Why?
|
| Collagen | 2 | 2013 | 275 | 0.040 |
Why?
|
| Scapula | 1 | 2021 | 16 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 500 | 0.040 |
Why?
|
| Ilium | 1 | 2021 | 25 | 0.040 |
Why?
|
| Employment | 1 | 2021 | 71 | 0.040 |
Why?
|
| Accreditation | 1 | 2021 | 85 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2021 | 99 | 0.040 |
Why?
|
| Cadaver | 1 | 2021 | 120 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 176 | 0.040 |
Why?
|
| Ribs | 1 | 2021 | 52 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 221 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 108 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 815 | 0.040 |
Why?
|
| Animals | 4 | 2014 | 33856 | 0.040 |
Why?
|
| Spine | 1 | 2021 | 151 | 0.040 |
Why?
|
| Mice | 2 | 2014 | 18215 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 520 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 429 | 0.040 |
Why?
|
| Workload | 1 | 2020 | 149 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 892 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2012 | 1110 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 317 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2024 | 2896 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1447 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 2830 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 505 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2021 | 406 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2022 | 707 | 0.030 |
Why?
|
| Rats | 2 | 2012 | 3383 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 1616 | 0.030 |
Why?
|
| Fibula | 1 | 2014 | 20 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 3320 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 2013 | 48 | 0.020 |
Why?
|
| Re-Epithelialization | 1 | 2012 | 15 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 109 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 2074 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4034 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2012 | 73 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3797 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 232 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 84 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2011 | 233 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 319 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 423 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2011 | 183 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2011 | 206 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 10015 | 0.020 |
Why?
|
| Quebec | 1 | 2009 | 5 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1016 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2009 | 203 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 448 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2009 | 425 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 600 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1484 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 875 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 517 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 852 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1599 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 2734 | 0.010 |
Why?
|
| Prevalence | 1 | 2011 | 2688 | 0.010 |
Why?
|
| Registries | 1 | 2011 | 1614 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 4672 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 5049 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 4669 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6800 | 0.010 |
Why?
|